StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2024 it was 96.5%.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2024Dec 31, 202496.5%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2025Mar 31, 202596.7%–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?